4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
LGC
主营:主营:体外转录、基因克隆(BAC克隆试剂盒)、感受态细胞(TG1噬菌体文库构建感受态)、体外转录、转座子突变、蛋白表达
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Routine_cell_strain > Lucigen/ClearColi®;K-12电性能电池/60850-1/12 rxns(DUOs)
商品详细Lucigen/ClearColi®;K-12电性能电池/60850-1/12 rxns(DUOs)
Lucigen/ClearColi®;K-12电性能电池/60850-1/12 rxns(DUOs)
Lucigen/ClearColi®;K-12电性能电池/60850-1/12 rxns(DUOs)
商品编号: 60850-1
品牌: LGC
市场价: ¥5480.00
美元价: 3288.00
产地: 美国(厂家直采)
公司:
产品分类: 常规细胞株
公司分类: Routine_cell_strain
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Eliminateendotoxinsatthesource

  • GeneticallymodifiedLPSdoesnottriggerendotoxicresponseinmammaliancells
  • PlasmidyieldssimilartoDH10Bcells
  • Idealformammaliantransfectionandproteinexpression
  • Skipexpensive,timeconsumingendotoxinremovalsteps
  • Frequentlyaskedquestions

  • Introduction
  • Genotypeinformation
  • Whyendo-freeplasmidprepisnotthebestmethod
  • PlasmidproductionwithClearColi
  • Endotoxicity/LALlevels
  • TransfectionandproteinexpressionfromClearColiPlasmids
  • GrowthratesforClearColiK-12cells
  • Usefulreferencearticles
  • ClearColilicensinginformation

IntroductiontoClearColi®technology:

Isthereabetterwaytoeliminateendotoxincontamination?
Nowthereis. 

Insteadofremovinglipopolysaccharide(LPS)contaminationfromyourproteinorplasmidDNApreparations,eliminatetheLPSatthesource. GeneticallymodifiedLPSfromanovel E.coli strainproducesfunctionallycleanrecombinantproteinsandplasmids. ClearColi®cellsarethefirstcommerciallyavailablecompetentcellswithamodifiedLPS(LipidIVA -seeFig.1)thatdoesnottriggertheendotoxicresponseinmammaliancells.ClearColicellslackoutermembraneagoNISTsforhTLR4/MD-2activation;therefore,activationofhTLR4/MD-2signallingbyClearColiisseveralordersofmagnitudelowercomparedwith E.coli wild-typecells,andplasmidDNApreparedfromClearColiisvirtuallyfreeofendotoxicactivity.AfterminimalpurificationfromClearColicells,proteinsorplasmids(whichmaystillcontain LipidIVA)canstillbeusedinmostapplicationswithoutelicitinganendotoxicresponse(seeEndotoxicityLALLevelsfordetails).

Figure1.TheLPSofanormalE.colicellcomparedtothegeneticallymodifiedLipidIVAfromClearColicells. InClearColi,theoligosaccharidechainhasbeendeleted,andtwoofthesixacylchainshavebeenremovedtodisabletheendotoxinsignal.

ModificationstothegenotypeoftheClearColicellsconsistofsevenseparategenedeletions,therebyensuringthatthereisnochanceofgeneticreversionbacktowildtypeandproductionofnormalLPS. ThesemutationsresultinthedeletionoftheoligosaccharidechainfromtheLPS,makingiteasiertoremovetheresultinglipidIVA fromthedownstreamproduct. Moreimportantly,twoofthesixacylchainsaredeleted. ThesixacylchainsoftheLPSarethetriggerthatisrecognizedbytheToll-likereceptor4(TLR4)incomplexwithmyeloiddifferentiationfactor2(MD-2),causingactivationofNF-ƙBandproductionofproinflammatorycytokines. LipidIVA,whichcontainsonlyfouracylchains,isnotrecognizedbyTLR4andthusdoesnottriggertheendotoxicresponse(seeFig.2).

ClearColi

Fig.2.ComparisonofrelativeNF-κBinductioninHEK-BlueCellsusingpurifiedLPSfromaK-12 E.coli strainorfrompure,syntheticallymanufacturedLipidIVA.

Backtotop▲


GenotypeInformation:

ClearColiK-12competentcellshavethefollowinggenotype:

F-,&lamBDa;- ΔendAΔrecAmsbA52frr181ΔgutQΔkdsDΔlpxLΔlpxMΔpagPΔlpxPΔeptA

Sevenspecificdeletionmutations(ΔgutQΔkdsDΔlpxLΔlpxMΔpagPΔlpxPΔeptA)encodethemodificationofLPStoLipidIVA,whileoneadditionalcompensatingmutation(msbA52)enablesthecellstomaintainviABIlityinthepresenceoftheLPSprecursorlipidIVA.

Backtotop▲


WhyEndo-freePlasmidPrepisnottheBestMethod

Topreventtoxicityincellstobetransfected,plasmidsproducedin E.colimustbeessentiallyfreeofendotoxin.However,efficienteliminationofendotoxinisachallengingtask,andendo-freeplasmidprepmethodsareexpensiveandtimeconsuming. ClearColiK-12cellsproduceplasmidDNAwithendotoxinlevelslessthanorequaltoplasmidspreppedfromstandardE.colicloninglinesandQiagen'sEndofreeMaxiPrepkits. 

ClearColiK-12cellsallowuseofstandardplasmidprepinsteadofendo-freemethods:

  • Savesupto90%inplasmidprepcosts
  • Saves1hourormoreinpreptime
  • Hightransfectionandproteinexpressionlevelswithoutconcernforendotoxincontamination

Backtotop▲


PlasmidProductionwithClearColiK-12Cells

ClearColiK-12cellsareendA-andrecA-forthehighestqualityplasmidproduction. PlasmidyieldsfromClearColiK-12cellsareequalorgreaterthanthoseobtainedfromnormalDH10Bcompetentcells. Table1comparesyieldsfrom1mLminiprepsforbothClearColiK-12andE.Cloni10G(equivalentOD'swereusedforbothpreps). 

 

PlasmidDNAYield
(standardminiprep)

ClearColiK-12

4.83µg/mL

E.Cloni10G

3.75µg/mL

 

Backtotop▲


Endotoxicity/LALLevels

Limulus amebocyteassaytestingisanFDA-approvedmethodfordetectionofendotoxinsandthemostcommonassayused. Asshowninfigure3,astandardplasmidpurificationstepforDNAproducedfromClearColicellsresultsinLALresponselevelslessthan1%ofthatproducedbyplasmidsderivedfromstandardDH10Bcellsandstandardprepmethods. TheEUlevelsdetectedfromClearColiK-12derivedplasmidsarealsoequivalentorlowerthantothoseobtainedfromDH10BderivedplasmidspreparedwithQiagen'sEndofreeMaxiprepkits(datanotshown).

Fig.3Comparisonofpost-plasmidpurificationendotoxinunitsdetectedfromClearColiK-12(redbars)andDH10B(E.cloni10G,greybars)competentcells.PlasmidDNAfromClearColidemonstratessignificantreductioninEU/mgwithouttheneedforendotoxinfreeplasmidprepkits.

 

ItshouldbenotedthattheresidualEUmeasurementsarelikelyduetothenon-specificnatureoftheLALassayunlessextraneousLPScontaminationfromothersourcesispresent.TheLALassayisactivatedsolelybythe4´-monophosphoryldiglucosaminebackboneofLPS. LALactivityisminimallyinfluencedbyacylationpatternofLPS,thekeydeterminantofendotoxicityineukaryoticcells. TheLALassayalsorecognizesawiderspectrumofLPS/lipidAvariantsthanthecentralcellularendotoxinsensorsystemofthehumanimmunecellsystem. Assuch,falsepositiveresultscanandwillresultduetothelackofspecificityoftheassay.

Alternativetoxicityassays,suchasthoseusingHEK-Bluecells(seeClearColi®BL21(DE3)cellsformoreinformation)suggestthateveninthepresenceofEUlevelsabovethreshholdsnormallytargetedbyresearchers,theactualimmunogeniceffectsfromClearColi-derivedproductsarenon-existent. Duetothenon-specificityoftheLALassaywhencombinedwithlipidIVA fromClearColi,itissuggestedthatresearchersconsideralternativemethodsofendotoxinmeasurement.

Backtotop▲


TransfectionandproteinexpressionfromClearColiPlasmids

Withtheoriginalsourceofendotoxineliminated,itisnowpossIBLetotransfectplasmidDNApreppedwithstandardmethodsdirectlyintohumanorothermammaliancelllineswithoutconcernforcellviability,alteredcellularresponsesorpoorproteinexpression. Toprovethis,aplasmid(pME-HA)containingageneencodingafluorescentproteinwasclonedintobothClearColiK-12andDH10BE.coli. TheplasmidfromClearColiwasthenisolatedviastandardQiagenMaxiprepkitmethod,whiletheplasmidfromDH10BwasisolatedusingQiagen'sEndofreeMaxiKit. TheresultingplasmidsweretransfectedintoHEK293Tcellsforproteinexpression(Figure4).  Nodifferencesincellviabilityorproteinexpressionlevelshavebeenobservedwhenusinganon-endofreeplasmidprepmethodincombinationwithClearColi-derivedplasmids. 

Figure4.ComparisonofexpressionofagreenfluorescentproteininHEK293TcellsfromClearColi-derivedplasmidsandstandardmaxiprep(left)vs.DH10B-derivedplasmidsandendofreemaxiprep(right).Theupperpanelsshowfluorescence;thelowerpanelsshowacombinedfluorescenceandbrightfieldimage.

Backtotop▲


GrowthRatesforClearColiK-12Cells

ClearColiK-12cellsgrowatapproximately50%oftherateofnormalDH10Bcells(seeFig.5). Usersshouldexpecttoseeverysmallcoloniesforthefirst24hoursafterplatingtransformants. Lucigenrecommendsincubatingplatesfor32-40hoursbeforepickingcoloniesforfutureexperiments. Whengrowntosufficientdensities,ClearColiK-12cellsproducesimilarplasmidyieldsasnormalDH10Bcells.

Figure5.ComparisonofgrowthratesforClearColiK12ElectrocompetentCellsvs.E.cloni 10GELITEElectrocompetentcells. CellsweretransformedwithpME-HA-CometandinoculatedtoaninitialOD600 of~0.01in200mLofLBMillermediumandgrownat37°Cwithshakingat210rpm.TheOD600 ofthecultureswasrecordedeveryhalfhour.

Backtotop▲


RelevantReferenceArticles:

  • Teghanemt,etal,MolecularBasisofReducedPotencyofUnderacylatedEndotoxins,JImmunol,2005;175:4669-4676
  • Mamat,etal,SingleaminoacidsubstitutionsineitherYhjDorMsbAconferviabilityto3-deoxy-D-manno-oct-2-ulosonicacid-depletedEscherichiacoli,MolecularMicroBIOLOGy,2008,67(3),633–648
  • Meredith,etal,RedefiningtheRequisiteLipopolysaccharideStructureinEscherichiacoli,ACSChemicalBiology,2006,1(1),33-42
  • Brandenburg,etal,TheExpressionofEndotoxicActivityintheLimulusTestasComparedtoCytokineProductioninImmuneCells,CurrentMedicinalChemistry,2009,16,2653-2660
  • Gutsmann,etal.StructuralprerequisitesforendotoxicactivityintheLimulustestascomparedtocytokineproductioninmononuclearcells,InnateImmunity,2010,16(1),39-47
  • BeomSeokPark1etal.,ThestructuralbasisoflipopolysacchariderecognitionbytheTLR4–MD-2complex,Nature458,1191-1195(30April2009)

Backtotop▲


ClearColiLicensingInformation:

ClearColiCompetentcellsaresubjecttoUSPatent8,303,964andotherUSandforeignpendingpatents.

LucigenCorporation("Lucigen")hasalicensefromResearchCorporationTechnologiestosellClearColicompetentcellstothird-partiesfornon-commercialresearchpurposesonly.Aseparatelicenseisrequiredforanycommercialuse.Formoreinformationabouttheuseofthisproductbycommercialentities,pleasereviewour fulllicensingpage.

Backtotop▲


ORDERINFORMATION

EachClearColi®K-12ElectocompetentCellKitcontains:ClearColiK-12ElectrocompetentCellsinDUOpackaging(2transformationspertube),RecoveryMedium,andpUC19PositiveControlPlasmid. Completeprotocolsareavailableonlineatwww.lucigen.com/manuals. 

RecoveryMediumisalsoavailableseparately,catalog#80026-1.

Forresearchuseonly. Notforhumanordiagnosticuse.

品牌介绍
美国Lucigen公司,自1998年成立至今,一直致力于生命科学领域相关科研产品的研究与开发,在分子生物学领域处于领导性地位。Lucigen公司主要开发各类用于基因克隆的试剂盒及相关产品,包括:CloneSmart®平端克隆试剂盒、BigEasy®线性克隆系统、pEZSeq™平端克隆试剂盒、ClonePlex™ AK文库构建试剂盒、DNA Terminator ®末端修复试剂盒、EconoTaq® DNA聚合酶及E.cloni感受态细胞等。Lucigen公司凭借其独到的产品技术,过硬的产品质量,良好的产品服务赢得了全球广大用户的信赖。